Miguel
Alcoceba Sánchez
Investigador desde 2011
Instituto de Biología Molecular y Celular del Cáncer de Salamanca / Centro de Investigación del Cáncer
Salamanca, EspañaPublicaciones en colaboración con investigadores/as de Instituto de Biología Molecular y Celular del Cáncer de Salamanca / Centro de Investigación del Cáncer (16)
2023
-
Detection and characterization of the novel HLA-DPA1*02:66:02N allele, with a premature stop codon in exon 2
Human Immunology, Vol. 84, Núm. 4, pp. 296-300
-
Primary Cutaneous Marginal Zone Lymphoproliferative Disorder of Donor Origin after Allogeneic Hematopoietic Stem Cell Transplantation
American Journal of Dermatopathology, Vol. 45, Núm. 6, pp. 378-382
2021
-
Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative
Annals of Hematology, Vol. 100, Núm. 3, pp. 825-830
2020
-
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
Blood Cancer Journal, Vol. 10, Núm. 10
2019
-
Immunoglobulin gene rearrangement IGHV3-48 is a predictive marker of histological transformation into aggressive lymphoma in follicular lymphomas
Blood Cancer Journal, Vol. 9, Núm. 7
2016
-
High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma
Annals of Hematology, Vol. 95, Núm. 2, pp. 253-262
2015
2013
-
Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma
British Journal of Haematology, Vol. 163, Núm. 2, pp. 223-234
2012
-
Molecular characterization of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma: Antigen-driven origin and IGHV4-34 as a particular subgroup of the non-GCB subtype
American Journal of Pathology, Vol. 181, Núm. 5, pp. 1879-1888
2011
2010
-
BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)
Annals of Hematology, Vol. 89, Núm. 5, pp. 453-458
-
Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients
Haematologica, Vol. 95, Núm. 5, pp. 745-751
2009
-
High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics
Leukemia Research, Vol. 33, Núm. 12, pp. 1706-1709
-
Primary cutaneous T-cell lymphoproliferative disorder of donor origin after allogeneic haematopoietic stem-cell transplantation
Clinical and Experimental Dermatology, Vol. 34, Núm. 8
2008
-
Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma
British Journal of Haematology, Vol. 141, Núm. 2, pp. 212-215
-
The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia
Haematologica, Vol. 93, Núm. 12, pp. 1797-1805